Conexeu Sciences Inc. is an early-stage medical technology company. The Company is focused on developing regenerative biomaterials that address significant needs in wound care, dentistry, and aesthetics. The Company is focused on providing physicians with device-based solutions for healing, restoring soft tissue, and improving patient outcomes across multiple clinical settings. Its core device candidate, CXU, is a temperature-responsive ECM scaffold formulation intended to transition in-situ to a gel-like extra cellular matrix (ECM) within approximately minutes (Ten-Minute Tissue). The Company operates and manages its business in one operating segment, which is developing and commercializing novel cellular therapies for skin restoration in wound care and aesthetics.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-09-25	US$3.890	-1.77%	111,143
26-09-24	US$3.960	-5.94%	163,668
26-09-23	US$4.210	-4.32%	235,356
26-09-22	US$4.400	-7.37%	158,301
26-09-21	US$4.750	-4.23%	138,302

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.890USD

Average target price

20.00USD

Spread / Average Target

+414.14%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq 16:00:00 2026-09-25 EDT			5-day change	1st Jan Change
3.890 ^USD	-1.77%		-26.60%	-

09-20	Conexeu Sciences Inc.(NasdaqCM:CNXU) added to S&P TMI Index	CI
09-14	Conexeu Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026	CI

Market Cap	110M 96.28M 90.93M 82.87M 155M 10.52B 156M 1.09B 421M 5.37B 412M 403M 17.27B	P/E 2026 *	-9.73x	P/E 2027 *	-7.34x
Enterprise Value	110M 96.28M 90.93M 82.87M 155M 10.52B 156M 1.09B 421M 5.37B 412M 403M 17.27B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	50.6%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	CNXU	Delayed
CBOE	CNXU	Real-time

09-20	Conexeu Sciences Inc.(NasdaqCM:CNXU) added to S&P TMI Index	CI
09-14	Conexeu Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026	CI
08-18	Conexeu Sciences Advances CXU Platform And Completes 12-Month P.R.O.O.F. Phase Of Preclinical Program	CI
07-14	Conexeu Sciences Details Completion Of 12-Month P.R.O.O.F. Preclinical Study For CXU Platform	CI
07-07	Conexeu Sciences Completes 12-Month Preclinical P.R.O.O.F Study for Cxu Platform and Announces Planned Move into Medical Aesthetics Market	CI
06-25	Conexeu Sciences Opens New Research and Development Facility At Admare M4 Innovation Centre in Vancouver	CI
06-25	Alert tagged to multiple companies from a research report withdrawn	RE
06-22	HC Wainwright Initiates Conexeu Sciences at Buy With $20 Price Target	MT
06-15	Conexeu Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026	CI
06-15	Conexeu Sciences Inc. Announces Management and Committee Changes, Effective June 15, 2026	CI
06-08	Conexeu Sciences Inc. Reports Manufacturing Scale Up And Regulatory Progress For Lead CXU Wound Care Program	CI
05-28	Conexeu Sciences Initiates Preclinical Development Program for B.R.E.A.S.T. Bioregenerative Matrix Platform with Wake Forest Institute for Regenerative Medicine	CI
05-21	Conexeu Sciences Inc.(NasdaqCM:CNXU) added to NASDAQ Composite Index	CI

Conexeu Sciences Inc. Stock

Stocks

CNXU

US20715F1003

Biotechnology & Medical Research

Valuation: Conexeu Sciences Inc.

Chart: Conexeu Sciences Inc.

Latest news: Conexeu Sciences Inc.

Analysts' recommendations: Conexeu Sciences Inc.

Press Releases: Conexeu Sciences Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Conexeu Sciences Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

09-01	Conexeu Sciences Sets September and October 2026 Conference Schedule	AQ
08-18	A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.	AQ
08-18	The Biggest Winners Don't Compete in a Category. They Rewrite It. One Company Is Betting It Can Too.	AQ
08-18	Conexeu Sciences : Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration	PU
08-12	The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For	AQ

1 day	-1.77%
1 week	-26.60%
Current month	-45.78%
1 month	-50.19%
3 months	-63.61%

1 week	3.82	5.02
1 month	3.82	7.51
Current year	3.82	18.79
1 year	3.82	18.79
3 years	3.82	18.79
5 years	3.82	18.79
10 years	3.82	18.79

Manager	Title	Age	Since
Miles Harrison CEO	Chief Executive Officer	61	2025-10-22
Claudia Chavez-Munoz CTO	Chief Tech/Sci/R&D Officer	46	2023-10-15
David Bogart PRN	Corporate Officer/Principal	56	2026-06-14

Director	Title	Age	Since
David Bogart BRD	Director/Board Member	56	2023-11-12
Jeffrey Nathan Sharpe CHM	Chairman	54	2025-10-22
Miles Harrison BRD	Director/Board Member	61	2025-10-22

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
9/14/26	Jeffrey Nathan Sharpe	Exercice	Chairman	1,000,000	3.7372%
5/26/26	Michael Wright	Exercice		800,000	-	-
5/22/26	Jeffrey Nathan Sharpe	Exercice	Chairman	1,000,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CONEXEU SCIENCES INC.	-1.77%	-26.60%	-	-	112M
LONZA GROUP AG	-0.14%	+4.44%	+8.50%	+33.52%	48.01B
IQVIA HOLDINGS INC.	-1.69%	+0.35%	+49.18%	+36.04%	45.27B
BEONE MEDICINES AG	+0.24%	+2.09%	+9.40%	+89.34%	40.93B
REVOLUTION MEDICINES, INC.	+2.56%	+4.08%	+370.76%	+583.23%	42.84B
CELLTRION, INC.	-0.62%	-1.61%	+5.30%	+46.02%	29.6B
MEDPACE HOLDINGS, INC.	-0.28%	+0.60%	+24.44%	+155.01%	17.32B
EUROFINS SCIENTIFIC SE	-0.46%	+0.62%	+24.98%	+41.01%	15.34B
ASCENDIS PHARMA A/S	-2.21%	-5.62%	-	-	15.15B
TEMPUS AI, INC.	+3.37%	+5.79%	+7.30%	-	14.84B
Average	-0.10%	-1.61%	+62.48%	+140.60%	26.94B
Weighted average by Cap.	+0.08%	+1.54%	+78.59%	+152.76%

	2026 *	2027 *
Net sales	-	-
Net income	-9.51M -8.35M -7.88M -7.18M -13.45M -912M -13.54M -94.33M -36.54M -466M -35.71M -34.94M -1.5B	-14.78M -12.97M -12.25M -11.16M -20.9M -1.42B -21.05M -147M -56.78M -724M -55.5M -54.3M -2.33B
Net Debt	-	-